Cancer · 2016 · 40 citations · 32 references
MedicineImmunologyOncologyGastrointestinal OncologyImmunotherapyRadionuclide TherapyAdjuvant ImmunotherapyCancer ImmunotherapyColorectal CancerImmunotherapy SafetyLiver MetastasisNeoadjuvant ImmunotherapyColorectal Cancer Adjuvant TherapyColorectal Cancer Neoadjuvant TherapyColorectal Liver MetastasisLiver Metastases ManagementLiver Metastases TreatmentLiver Tumor TherapyMetastatic Liver Disease TreatmentNeoadjuvant Chemoimmunotherapy
BACKGROUND In previous work, a single administration of anticarcinoembryonic antigen (anti‐CEA) 131 I‐labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy. METHODS Sixty‐three patients (median age, 64.5 years) received RIT at 40 to 50 millicuries/m 2 per dose. Before the receipt of RIT, restaging was performed with computed tomography/magnetic resonance imaging and 18 F‐fluorodeoxyglucose–positron emission to confirm that patients were “truly adjuvant.” Patients who had elevated serum CEA levels or radiographically inconclusive new lesions were classified as “possibly nonadjuvant,” but they also received RIT. Time to progression (TTP), overall survival (OS), and cause‐specific survival (CSS) were calculated. The median follow‐up was 54 months. RESULTS After the first course of RIT, 14 of 63 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity; 19 patients did not receive the second course of RIT because of impaired performance status (N = 5) or relapse (N = 14). After the second course of RIT, 9 of 44 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity. Five patients developed myelodysplastic syndrome (MDS) from 22 to 55 months after their last RIT. The median TTP, OS, and CSS for all patients were 16, 55, and 60 months, respectively. The “truly adjuvant” patients (N = 39) had an improved median TTP (not reached vs 6.1 months; hazard ratio, 0.12; P < .001), OS (75.6 vs 33.4 months; hazard ratio, 0.44; P = .014), and CSS (not reached vs 41.4 months; hazard ratio,0.42; P = .014) compared with “possibly nonadjuvant” patients (N = 24). CONCLUSIONS Repeated RIT with 131 I‐labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for “truly adjuvant” patients. However, the maximum safe dose of 131 I‐labetuzumab is a single administration of 50 millicuries/m 2 . Cancer 2017;123:638–649. © 2016 American Cancer Society .
32
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.5K citations · Full text
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
Yuman Fong, Joseph G. Fortner, Ruth L. Sun et al. · Annals of Surgery · 1999 · 3.7K citations · Full text
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg, Heinz Tuechler, Julie Schanz et al. · Blood · 2012 · 3.1K citations · Full text
Epidemiology and Management of Liver Metastases From Colorectal Cancer
Sylvain Manfrédi, Côme Lepage, Cyril Hatem et al. · Annals of Surgery · 2006 · 1.4K citations · Full text